Free Trial
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.81
-6.7%		$0.95
$0.81
▼
$3.20
$242.02M0.186.56 million shs7.45 million shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.21
-1.9%		$13.30
$6.39
▼
$26.95
$875.70M1.441.29 million shs1.88 million shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$14.15
+2.8%		$18.98
$8.36
▼
$28.00
$875.74M1.641.01 million shs1.67 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$10.52
-1.4%		$11.32
$7.36
▼
$13.90
$949.21M0.471.81 million shs1.64 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-0.58%-5.07%-10.39%-38.92%-70.39%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-1.42%-9.64%-27.66%-35.74%+51.53%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.68%-1.99%-30.80%-38.75%+52.32%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+1.33%-0.37%-19.47%-11.67%+13.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.81
-6.7%		$0.95
$0.81
▼
$3.20
$242.02M0.186.56 million shs7.45 million shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$10.21
-1.9%		$13.30
$6.39
▼
$26.95
$875.70M1.441.29 million shs1.88 million shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$14.15
+2.8%		$18.98
$8.36
▼
$28.00
$875.74M1.641.01 million shs1.67 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$10.52
-1.4%		$11.32
$7.36
▼
$13.90
$949.21M0.471.81 million shs1.64 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-0.58%-5.07%-10.39%-38.92%-70.39%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-1.42%-9.64%-27.66%-35.74%+51.53%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.68%-1.99%-30.80%-38.75%+52.32%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+1.33%-0.37%-19.47%-11.67%+13.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.43
Hold$3.90378.65% Upside
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$33.33226.48% Upside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.90
Moderate Buy$51.75265.72% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.77
Moderate Buy$25.69144.18% Upside

Current Analyst Ratings Breakdown

Latest AKBA, KURA, CRVS, and JBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/2/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
10/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$47.00
10/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
10/1/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$30.00
9/16/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/15/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
9/11/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/8/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Westpark Capital logo
Westpark Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$4.50
8/31/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M0.96N/AN/A$0.12 per share6.79
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.12 per share82.13$0.73 per shareN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.74 per shareN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M13.87N/AN/A$2.00 per share5.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.11N/AN/AN/A-13.54%-88.88%-7.74%11/9/2026 (Estimated)
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.61N/AN/AN/AN/A-36.15%-33.62%11/3/2026 (Estimated)
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$1.92N/AN/AN/AN/A-49.11%-45.62%N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)

Latest AKBA, KURA, CRVS, and JBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1921N/AN/AN/AN/AN/A
11/3/2026Q3 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8144N/AN/AN/A$23.81 millionN/A
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/10/2026Q2 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.66-$0.76-$0.10-$0.76N/AN/A
8/6/2026Q2 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1591-$0.19-$0.0309-$0.19N/AN/A
8/5/2026Q2 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0420-$0.02+$0.0220-$0.03$48.85 million$49.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.99
1.43
1.35
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
16.16
16.16
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
14.93
14.93
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
194277.11 million265.19 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3784.12 million67.55 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
5563.60 million48.93 millionN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26088.96 million82.20 millionOptionable

Recent News About These Companies

UBS reaffirms Buy for Kura Oncology stock at USD 15 target
October 7 at 10:08 PM  |  ad-hoc-news.deA
Kura Oncology stock heads into October 13 webcast focus on KO-7246
October 7 at 10:08 PM  |  ad-hoc-news.deA
Kura Oncology (NASDAQ:KURA) Shares Climb 4.2% - What's Next?
October 7 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-kura-oncology-nasdaq-kura-shares-climb-42-whats-next-2026-10-07/
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
October 7 at 12:06 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/caspian-therapeutics-and-kura-oncology-to-host-investor-webcast-highlighting-caspian-s-launch-and-ko-7246-preclinical-data-in-diabetes-1036604517
Caspian Therapeutics and Kura Oncology to Host Investor Webcast on Caspian Formation and KO-7246 Data from EASD Meeting
October 7 at 7:30 AM  |  quiverquant.comQ
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
October 7 at 7:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376372/35186/en/caspian-therapeutics-and-kura-oncology-to-host-investor-webcast-highlighting-caspian-s-launch-and-ko-7246-preclinical-data-in-diabetes.html
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 4, 2026  |  biospace.comB
JPMorgan Chase & Co. Initiates Coverage on Kura Oncology (NASDAQ:KURA)
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081550
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and AbbVie (ABBV)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/4920940/analysts-offer-insights-on-healthcare-companies-kura-oncology-kura-and-abbvie-abbv/
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373755/35186/en/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Kura Oncology CMO Mollie Leoni Sells 41,250 Shares Post-PSU Vesting
October 1, 2026  |  kalkinemedia.comK
JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target
October 1, 2026  |  marketscreener.comM
This biotech making precision medicines for cancer could nearly triple, says JPMorgan
October 1, 2026  |  cnbc.comhttps://www.cnbc.com/2026/10/01/this-biotech-making-precision-medicines-for-cancer-could-nearly-triple-says-jpmorgan.html
Kura Oncology (NASDAQ:KURA) Now Covered by JPMorgan Chase & Co.
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-kura-oncology-nasdaq-kura-now-covered-by-jpmorgan-chase-co-2026-10-01/
Kura Oncology (NASDAQ:KURA) Stock: Insider Kathleen Ford Sells 6,906 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073392
Kura Oncology (NASDAQ:KURA) Stock: Insider Thomas James Doyle Sells 4,607 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073389
Kura Oncology (NASDAQ:KURA) Stock: Insider Teresa Brophy Bair Sells 8,442 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073388
Kura Oncology (NASDAQ:KURA) Stock: Insider Brian Powl Sells 15,430 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073141
Kura Oncology (NASDAQ:KURA) Stock: Insider Mollie Leoni Sells 12,448 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073136
Kura Oncology (NASDAQ:KURA) Stock: Insider Brian Powl Sells 17,020 Shares
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073134
Kura Oncology (NASDAQ:KURA) Stock: Insider Kathleen Ford Sells 3,668 Shares
September 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-kura-insider-buying-and-selling-2026-09-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$0.81 -0.06 (-6.71%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 +0.01 (+1.74%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$10.21 -0.20 (-1.92%)
Closing price 04:00 PM Eastern
Extended Trading
$10.10 -0.11 (-1.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$14.15 +0.38 (+2.76%)
Closing price 04:00 PM Eastern
Extended Trading
$14.14 -0.02 (-0.11%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$10.52 -0.15 (-1.41%)
Closing price 04:00 PM Eastern
Extended Trading
$10.51 -0.01 (-0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas